From Name:
From Email:
To Name:
To Email:

Optional Message:


FDA committee recommends against ACS for rivaroxaban

from Forbes

The Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee voted against adding an indication for acute coronary syndromes to the label of the anticoagulant rivaroxaban. The advisory panel spent most of the day trying to reconcile diametrically opposed views of the pivotal ATLAS ACS 2-TIMI 51 trial. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063